• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Aaron Lyss on What the Next Oncology Payment Model Should Include

Video

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

Transcript:

What would you like to see in the next iteration of a payment model for oncology?

I think there are 4 parameters that are critical to alternative payment models in oncology. The first is benchmarking. Are the performance benchmarks associated with the model achievable and reasonable for the practices who are participating? I think the second important issue is control and accountability. By that,I mean, does a practice, do providers have control over the outcomes of the model? Can they then be held accountable for their performance? Then I think the third issue is what I'll refer to as bilateralism. That's basically, is the payment structure of the model suitable both to the provider group as well as to the payer, based on the value that the practice can create in the model? Then the fourth issue is scalability. Does the model apply to a broad enough population of patients that enables the practice to focus on all the improvements in care delivery that they want to see across a very broad population? Then from the payer perspective, does the model work for a broad enough population of practices that it can apply to a nationwide cohort of practices who would be participating?

Related Videos
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.